CW prepared the majority of the first draft while all other authors contributed further sections. All authors contributed to manuscript revision, read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
We gratefully acknowledges support from the 7th Framework Program of the European Union (METOXIA project; HEALTH-F2-2009-222741), from the UK Engineering and Physical Sciences Research Council [IMPACT programme Grant (EP/K-34510/1)] and from the Edinburgh Cancer Centre research endowment/Edinburgh and Lothians Health Foundation fund.
Wang GL, Jiang BH, Rue EA, Semenza GL.Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A.1995;92:5510–4. [DOI] [PubMed] [PMC]
Doe MR, Ascano JM, Kaur M, Cole MD.Myc posttranslationally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res.2011;72:949–57. [DOI] [PubMed] [PMC]
Ippolito L, Morandi A, Giannoni E, Chiarugi P.Lactate: a metabolic driver in the tumour landscape. Trends Biochem Sci.2019;44:153–66. [DOI] [PubMed]
Warburg O.On respiratory impairment in cancer cells. Science.1956;124:269–70. [PubMed]
Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supuran CT, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev.2013;39:171–9. [DOI] [PubMed]
Semenza GL.Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol.2009;19:12–6. [DOI] [PubMed]
Putney LK, Denker SP, Barber DL.The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions. Ann Rev Pharmacol Toxicol.2002;42:527–52. [DOI] [PubMed]
Ullah MS, Davies AJ, Halestrap P.The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem.2006;281:9030–7. [DOI] [PubMed]
Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL.New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene.2010;29:6509–21. [DOI] [PubMed]
Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, et al. The SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Res.2014;74:5507–19. [DOI] [PubMed]
Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer.2007;97:646–53. [DOI] [PubMed] [PMC]
Harguindey S, Arranz JL, Orozco JDP, Rauch C, Fais S, Cardone RA, et al. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. J Trans Med.2013;11:282. [DOI]
Webb BA, Chimenti M, Jacobson MP, Barber DL.Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer.2011;11:671–7. [DOI] [PubMed]
Zhang X, Lin Y, Gillies RJ.Tumor pH and its measurement. J Nucl Med.2010;51:1167–70. [DOI] [PubMed] [PMC]
Chiche J, IIc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res.2009;69:358–68. [DOI] [PubMed]
Bristow RG, Hill RP.Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer.2008;8:180–92. [DOI] [PubMed]
Gerweck LE, Vijayappa S, Kozin S.Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther.2006;5:1275–9. [DOI] [PubMed]
Hunter A, Hendrikse A, Renan M, Abratt R.Does the tumor microenvironment influence radiation-induced apoptosis?Apoptosis. 2006;11:1727–35. [DOI] [PubMed]
Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC.Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol.2000;2:318–25. [DOI] [PubMed]
Schreiber R.Ca2+ signalling, intracellular pH and cell volume in cell proliferation. J Membr Biol.2005;205:129–37. [DOI] [PubMed]
Parks SK, Chiche J, Pouysségur J.Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer.2013;13:611–23. [DOI] [PubMed]
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res.2000;60:916–21. [PubMed]
Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res.2013;73:1524–35. [DOI] [PubMed] [PMC]
Rofstad EK, Matiesen B, Kindem K, Galappathi K.Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res.2006;66:6699–707. [DOI] [PubMed]
Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E.CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem.2004;279:26991–7007. [DOI] [PubMed]
Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ.Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res.2006;66:5216–23. [DOI] [PubMed]
Kim R, Emi M, Tanabe K.Cancer immunoediting from immune surveillance to immune escape. Immunology.2007;121:1–14. [DOI] [PubMed] [PMC]
Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G.Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res.2011;71:5601–5. [DOI] [PubMed]
Kareva I, Hahnfeldt P.The emerging “Hallmarks” of metabolic reprogramming and immune evasion: distinct or linked?Cancer Res. 2013;73:2737–42. [DOI] [PubMed]
Lardner A.The effects of extracellular pH on immune function. J Leukoc Biol.2001;69:522–30. [DOI] [PubMed]
Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E.Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer.2012;131:633–40. [DOI] [PubMed]
Xu L, Fukumura D, Jain RK.Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signalling pathway: mechanism of low pH-induced VEGF. J Biol Chem.2002;277:11368–74. [DOI] [PubMed]
Seliger C, Leukel P, Moeckel S, Jachnik B, Lottaz C, Kreutz M, et al. Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitro. PloS One.2013;8:e78935. [DOI] [PubMed] [PMC]
Rafiee P, Nelson VM, Manley S, Wellner M, Floer M, Binion DG, et al. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kB. Am J Physiol Gastrointest Liver Physiol.2009;296:G388–98. [DOI] [PubMed]
Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood.2006;107:2013–21. [DOI] [PubMed]
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood.2007;109:3812–9. [DOI] [PubMed]
Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res.2012;72:2746–56. [DOI] [PubMed]
Husain Z, Huang Y, Seth P, Sukhatme VP.Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol.2013;191:1486–95. [DOI] [PubMed]
Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle.2011;10:1271–86. [DOI] [PubMed] [PMC]
Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ.2011;18:829–40. [DOI] [PubMed] [PMC]
Rattigan YI, Patel BB, Ackerstaff E, Sukenick G, Koutcher JA, Glod JW, et al. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res.2012;318:326–35. [DOI] [PubMed] [PMC]
Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W.Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol.2011;39:453–63. [DOI] [PubMed]
Végran F, Boidot R, Michiels C, Sonveaux P, Feron O.Lactate influx through the endothelial cell monocarboxylae transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res.2011;71:2550–60. [DOI] [PubMed]
Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol.2010;94:102–9. [DOI] [PubMed]
Groussard C, Morel I, Chevanne M, Monnier M, Cillard J, Delamarche A.Free radical scavenging and antioxidant effects of lactate ion: an in vitro study. J Appl Physiol.2000;89:169–75. [DOI] [PubMed]
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem.2015;30:689–721. [DOI] [PubMed]
Damaghi M, Wojtkowiak JW, Gillies RJ.pH sensing and regulation in cancer. Front Physiol.2013;4:370. [DOI] [PubMed] [PMC]
Reshkin SJ, Bellizzi A, Caldiera S, Albarani V, Malanchi I, Poignee M, et al. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays a central role in the development of subsequent transformation-associated phenotypes. FASEB J.2000;14:2185–97. [DOI] [PubMed]
Provost JJ, Wallert MA.Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression. Chem Biol Drug Des. 2013:81:85–101. [DOI] [PubMed]
Pedersen SF.The Na+/H+ exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death. Pflugers Arch.2006;452:249–59. [DOI] [PubMed]
Amith SR, Fliegel L.Regulation of the Na+/H+ exchanger (NHE1) in breast cancer metastasis. Cancer Res.2013;73:1259–64. [DOI] [PubMed]
Baumgartner M, Patel H, Barber DL.Na+/H+ exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes. Am J Physiol Cell Physiol.2004;287:C844–50. [DOI] [PubMed]
Malo ME, Li L, Fliegel L.Mitogen-activated protein kinase-dependent activation of the Na+/H+ exchanger is mediated through phosphorylation of amino acids Ser770 and Ser771. J Biol Chem.2007;282:6292–9. [DOI] [PubMed]
Takahashi E, Abe J, Gallis B, Aebersold R, Spring DJ, Krebs EG, et al. P90 (RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. J Biol Chem.1999;274:20206–14. [DOI] [PubMed]
Bianchini L, L’Allemain G, Pouysségur J.The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors. J Biol Chem.1997;272:271–9. [DOI] [PubMed]
Tominaga T, Barber DL.Na-H exchange acts downstream of RhoA to regulate integrin-induced cell adhesion and spreading. Mol Biol Cell.1998;9:2287–303. [DOI] [PubMed] [PMC]
Karki P, Li X, Schrama D, Fliegel L.B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. J Biol Chem.2011;286:13096–105. [DOI] [PubMed] [PMC]
Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, et al. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell.2005;16:3117–27. [DOI] [PubMed] [PMC]
Stüwe L, Müller M, Fabian A, Waning J, Mally S, Noël J, et al. pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol.2007;585:351–60. [DOI] [PubMed] [PMC]
Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M, Paradiso A, et al. Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na+/H+ exchange, motility, and invasion induced by serum deprivation. J Biol Chem.2000;275:5361–9. [DOI] [PubMed]
Paradiso A, Cardone RA, Bellizi A, Bagorda A, Guerra L, Tommasino M, et al. The Na+-H+ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. Breast Cancer Res.2004;6:R616–28. [DOI] [PubMed] [PMC]
Lin Y, Chang G, Wang J, Jin W, Wang L, Li H, et al. NHE1 mediates MDA-MB-231 cells invasion through the regulation of MT1-MMP. Exp Cell Res.2011;317:2031–40. [DOI] [PubMed]
Götte M, Yip GW.Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res.2006;66:10233–7. [DOI] [PubMed]
Chang G, Wang J, Zhang H, Zhang Y, Wang C, Xu H, et al. CD44 targets Na+/H+ exchanger 1 to mediate MDA-MB-231 cells’ metastasis via the regulation of ERK1/2. Br J Cancer.2014;110:916–27. [DOI] [PubMed] [PMC]
Schneider L, Stock CM, Dieterich P, Jensen BH, Pedersen LB, Satir P, et al. The Na+/H+ exchanger NHE1 is required for directional migration stimulated via PDGFR-alpha in the primary cilium. J Cell Biol.2009;185:163–76. [DOI] [PubMed] [PMC]
Frantz C, Karydis A, Nalbant P, Hahn KM, Barber DL.Postitive feedback between Cdc42 activity and H+ efflux by the Na-H exchanger NHE1 for polarity of migrating cells. J Cell Biol.2007;179:403–10. [DOI] [PubMed] [PMC]
Beaty BT, Wang Y, Bravo-Cordero JJ, Sharma VP, Miskolci V, Hodgson L, et al. Talin regulates moesin-NHE1-1 recruitment to invadopodia and promotes mammary tumor metastasis. J Cell Biol.2014;205:737–51. [DOI] [PubMed] [PMC]
Srivastava J, Barreiro G, Groscurth S, Gingras AR, Goult BT, Critchley DR, et al. Structural model and functional significance of pH-dependent talin-actin binding for focal adhesion remodelling. Proc Natl Acad Sci U S A.2008;105;14436–41. [DOI] [PubMed] [PMC]
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res.1998;58:5123–9. [PubMed]
Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, et al. NBCn1 and NHE1 expression and activity in ΔNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. Exp Cell Res.2010;316:2538–53. [DOI] [PubMed]
Lauritzen G, Stock CM, Lemaire J, Lund SF, Jensen MF, Damsgaard B, et al. The Na+/H+ exchanger NHE1, but not the Na+, HCO3− cotransporter NBCn1, regulates the motility of MCF7 breast cancer expressing constitutively active ErbB2. Cancer Lett.2012;317:172–83. [DOI] [PubMed]
Akram S, Teong HF, Fliegel L, Pervaiz S, Clément MV.Reactive oxygen species-mediated regulation of the Na+/H+ exchanger 1 gene expression connects intracellular redox status with cells’ sensitivity to death triggers. Cell Death Differ.2006;13:628–41. [DOI] [PubMed]
Cong D, Zhu W, Shi Y, Pointer KB, Clark PA, Shen H, et al. Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H+ extrusion, cell migration and survival. Carcinogenesis.2014;35:2014–24. [DOI] [PubMed] [PMC]
Wu KL, Khan S, Lakhe-Reddy S, Wang L, Jarad G, Miller RT, et al. Renal tubular epithelial cell apoptosis is associated with caspase cleavage of the NHE1 Na+/H+ exchanger. Am J Physiol Renal Physiol.2003;284:F829–39. [DOI] [PubMed]
Wu KL, Khan S, Lakhe-Reddy S, Jarad G, Mukherjee A, Obejero-Paz CA, et al. The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival. J Biol Chem.2004;279:26280–6. [DOI] [PubMed]
Schelling JR, Abu Jawdeh BG.Regulation of cell survival by NA+/H+ exchanger 1. Am J Physiol Renal Physiol.2008;295:F625–32. [DOI] [PubMed] [PMC]
Cho YL, Lee KS, Lee SJ, Namkoong S, Kim YM, Lee H, et al. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Biochem Biophys Res Commun.2005;326:752–8. [DOI] [PubMed]
Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, et al. Repression of NHE1 expression by PPARγ activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res.2009;69:8636–44. [DOI] [PubMed]
Reshkin SJ, Bellizzi A, Cardone RA, Tommasino M, Casavola V, Paradiso A.Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res.2003;9:2366–73. [PubMed]
Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A.Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer.2005;115:924–9. [DOI] [PubMed]
He B, Deng C, Zhang M, Zou D, Xu M.Reduction of intracellular pH inhibits the expression of VEGF in K562 cells after targeted inhibition of the Na+/H+ exchanger. Leuk Res.2007;31:507–14. [DOI] [PubMed]
Mo XG, Chen QW, Li XS, Zheng MM, Ke DZ, Deng W, et al. Suppression of NHE1 by small interfering RNA inhibits HIF-1α-induced angiogenesis in vitro via modulation of calpain activity. Microvasc Res.2011;81:160–8. [DOI] [PubMed]
Rotin D, Steele-Norwood D, Grinstein S, Tannock I.Requirement of the Na+/H+ exchanger for tumor growth. Cancer Res.1989;49:205–11. [PubMed]
Pouysségur J, Franchi A, Pagès G.pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp.2001;240:186–96. [DOI] [PubMed]
Sailer BL, Barrasso AM, Valdez JG, Cobo JM, D’Anna JA, Crissman HA.Reduction in the radiation-induced late S phase and G2 blocks in HL-60 cell populations by amiloride, an efficient inhibitor of the Na+/H+ transporter. Cancer Res.1998;58:413–20. [PubMed]
Karmazyn M.Role of sodium-hydrogen exchanger in cardiac hypertrophy and heart failure: a novel and promising therapeutic target. Basic Res Cardiol.2001;96:325–8. [DOI] [PubMed]
Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, et al.;the Guard during ischemia against necrosis (GUARDIAN) Investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation.2000;102:3032–8. [DOI] [PubMed]
Rupprecht HJ, vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, et al. Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation.2000;101:2902–8. [DOI] [PubMed]
Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, et al. The Na+/H+ exchange inhibitor eniporide as an adjuct to early reperfusion therapy for acute myocardial infarction: results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol.2001;38:1644–50. [DOI] [PubMed]
Chaitman BR.A review of the GUARDIAN trial results: clinical implications and the significance of elevated perioperative CK-MB on 6-month survival. J Card Surg.2003;18Suppl 1:13–20. [DOI] [PubMed]
Avkiran M, Cook AR, Cuello F.Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?Curr Opin Pharmacol. 2008:8:133–40. [DOI] [PubMed]
Linz WLHWA, Albus U.Long-term treatment with the NHE1-inhibitor cariporide extends the normal lifespan of Wistar Kyoto rats. Eur Heart J.2001;22:148.
Li H, Chang G, Wang J, Wang L, Jin W, Lin Y, et al. Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress-CCAAT/enhancer binding protein homologous protein dependent mechanism. Leuk Lymphoma.2014;55:2135–40. [DOI] [PubMed]
Di Sario A, Bendia E, Omenetti A, De Minicis S, Marzioni M, Kleemann HW, et al. Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. Dig Liver Dis.2007;39:60–9. [DOI] [PubMed]
Kaminota T, Yano H, Shiota K, Nomura N, Yaguchi H, Kirino Y, et al. Elevated Na+/H+ exchanger-1 expression enhances the metastatic collective migration of head and neck squamous cell carcinoma cells. Biochem Biophys Res Commun.2017;486:101–7. [DOI] [PubMed]
Cardone RA, Greco MR, Zeeberg K, Zaccagnino A, Saccomano M, Bellizzi A.A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. Neoplasia.2015;17:155–66. [DOI] [PubMed] [PMC]
Chen Q, Liu Y, Zhu XL, Feng F, Yang H, Xu W.Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo. BMC Cancer.2019;19:211. [DOI] [PubMed] [PMC]
Voss NCS, Kold-Petersen H, Henningsen MB, Homilius C, Boedtkjer E.Upregulated Na+/H+-exchange protects human colon cancer tissue against intracellular acidification. Biomed Res Int.2019;2019:3702783. [DOI] [PubMed] [PMC]
Albatany M, Li A, Meakin S, Bartha R.In vivo detection of acute intracellular acidification in glioblastoma multiforme following a single dose of cariporide. Int J Clin Oncol.2018;23:812–9. [DOI] [PubMed]
Pivovarova AI, MacGregor GG.Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: feeding Warburg’s sweet tooth and blocking acid export as an anticancer strategy. Biomed Pharmacother.2018;98:173–9. [DOI] [PubMed]
Matthews H, Ranson M, Kelso MJ.Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?Int J Cancer. 2011;129:2051–61. [DOI] [PubMed]
Harguindey S, Orive G, Pedraz JL, Bello G, Arranz JL, Samaniego JM.Apparent cure of a case of metastatic ovarian carcinoma after chronic treatment with Na+-H+ antiport inhibitors. Oncologia.2002;25:62–6. Spanish.
Alliegro MC, Alliegro MA, Cragoe EJ Jr, Glaser BM.Amiloride inhibition of angiogenesis in vitro. J Exp Zool.1993;267;245–52. [DOI] [PubMed]
Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, et al. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma. Clin Cancer Res.2017:23:6602–15. [DOI] [PubMed]
Hosogi S, Miyazaki H, Nakajima K, Ashihara E, Niisato N, Kusuzaki K, et al. An inhibitor of Na+/H+ exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl− concentration via DIDS-sensitive pathways. Cell Physiol Biochem.2012;30:1241–53. [DOI] [PubMed]
Maidorn RP, Cragoe EJ Jr, Tannock IF.Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer.1993;67:297–303. [DOI] [PubMed] [PMC]
Rich IN, Worthington-White D, Garden OA, Musk P.Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger. Blood.2000;95:1427–34. [DOI] [PubMed]
Nagata H, Che XF, Miyazawa K, Tomoda A, Konishi M, Ubukata H, et al. Rapid decrease of intracellular pH associated with inhibition of Na+/H+ exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one. Oncol Rep.2011;25:341–6. [DOI] [PubMed]
Halestrap AP, Wilson MC.The monocarboxylate transporter family--role and regulation. IUBMB Life.2012;64:109–19. [DOI] [PubMed]
Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer.2011;11:312. [DOI] [PubMed] [PMC]
Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun.2014;451:54–61. [DOI] [PubMed]
Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch.2008;452:139–46. [DOI] [PubMed]
Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E.Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res.2006;66:632–7. [DOI] [PubMed]
Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y.Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis.2010;27:557–69. [DOI] [PubMed]
Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci.2011;102:1007–13. [DOI] [PubMed]
Sonveaux P, Copetti T, De Saedeleer CJ, Végran F, Verrax J, Kennedy KM, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One.2012;7:e33418. [DOI] [PubMed] [PMC]
Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A.2011;108:16663–8. [DOI] [PubMed] [PMC]
Kumar A, Kant S, Singh SM.α-Cyano-4-hydroxycinnamate induces apoptosis in Dalton’s lymphoma cells: role of altered cell survival-regulatory mechanisms. Anticancer Drugs.2013;24:158–71. [DOI] [PubMed]
Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia2011;13:620–32. [DOI] [PubMed] [PMC]
Simon S, Roy D, Schindler M.Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A.1994;91:1128–32. [DOI] [PubMed] [PMC]
Chen M, Huang SL, Zhang XQ, Zhang B, Zhu H, Yang VW, et al. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway. J Cell Biochem.2012;113:2474–87. [DOI] [PubMed] [PMC]
Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res.2014;74:908–20. [DOI] [PubMed] [PMC]
Kumar A, Kant S, Singh SM.Targeting monocarboxylate transporter by α-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis.2013;18:1574–85. [DOI] [PubMed]
Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther.2014;13:2805–16. [DOI] [PubMed] [PMC]
Schulze A, Harris AL.How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature.2012;491:364–73. [DOI] [PubMed]
Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P.Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol.2011;2:49. [DOI] [PubMed] [PMC]
Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res.2014;20:926–37. [DOI] [PubMed] [PMC]
Ke X, Fei F, Chen Y, Xu L, Zhang Z, Huang Q, et al. Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis.2012;33:1598–1607. [DOI] [PubMed] [PMC]
Xiong L, Edwards CK 3rd, Zhou L.The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci.2014;15:17411–41. [DOI] [PubMed] [PMC]
Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut.2009;58:1391–8. [DOI] [PubMed]
Xu T, Zhou M, Peng L, Kong S, Miao R, Shi Y, et al. Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer. Int J Clin Exp Pathol.2014;7:7432–41. [PubMed] [PMC]
Huang P, Chang S, Jiang X, Su J, Dong C, Liu X, et al. RNA interference targeting CD147 inhibits the proliferation, invasiveness, and metastatic activity of thyroid carcinoma cells by down-regulating glycolysis. Int J Clin Exp Pathol.2015;8:309–18. [PubMed] [PMC]
Guo H, Li R, Zucker S, Toole BP.EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res.2000;60:888–91. [PubMed]
Huang XQ, Chen X, Xie XX, Zhou Q, Li K, Li S, et al. Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol.2014;7:1651–66. [PubMed] [PMC]
Wu J, Li Y, Dang YZ, Gao HX, Jiang JL, Chen ZN.HAb18G/CD147 promotes radioresistance in hepatocellular carcinoma cells: a potential role for integrin β1 signaling. Mol Cancer Ther2015;14:553–63. [DOI] [PubMed]
Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, et al. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem.2009;284:16400–8. [DOI] [PubMed] [PMC]
Sennoune SR, Luo D, Martínez-Zaguilán R.Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys.2004;40:185–206. [DOI] [PubMed]
Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst.2004;96:1702–13. [DOI] [PubMed]
Sennoune SR, Bakunts K, Martínez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol.2004;286:C1443–52. [DOI] [PubMed]
Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res.2001;61:439–44. [PubMed]
Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res.2011;9:845–55. [DOI] [PubMed]
Pérez-Sayáns M, Reboiras-López MD, Somoza-Martín JM, Barros-Angueira F, Diz PG, Rey JM, et al. Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma. Cancer Biol Ther.2010;9:1057–64. [DOI] [PubMed]
von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem.2013;288:1385–96. [DOI] [PubMed] [PMC]
You H, Jin J, Shu H, Yu B, De Milito A, Lozupone F, et al. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Lett.2009;280:110–9. [DOI] [PubMed]
De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res.2007;67:5408–17. [DOI] [PubMed]
Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res.2005;65:6843–9. [DOI] [PubMed]
Supino R, Scovassi AI, Croce AC, Dal Bo L, Favini E, Corbelli A, et al. Biological effects of a new vacuolar-H+-ATPase inhibitor in colon carcinoma cell lines. Ann N Y Acad Sci.2009;1171:606–16. [DOI] [PubMed]
von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM.V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Mol Oncol.2014;8:9–19. [DOI] [PubMed] [PMC]
Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, et al. Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer.2013;133:843–54. [DOI] [PubMed]
Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol.1998;185:324–30. [DOI] [PubMed]
Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S, et al. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem.2003;134:359–64. [DOI] [PubMed]
Wu YC, Wu WK, Li Y, Yu L, Li ZJ, Wong CC, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun.2009;382:451–6. [DOI] [PubMed]
Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS.Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1α. Mol Pharmacol.2006;70:1856–65. [DOI] [PubMed]
Capecci J, Forgac M.The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. J Biol Chem.2013;288:32731–41. [DOI] [PubMed] [PMC]
Aiko K, Tsujisawa T, Koseki T, Hashimoto S, Morimoto Y, Amagasa T, et al. Involvement of cytochrome c and caspases in apoptotic cell death of human submandibular gland ductal cells induced by concanamycin A. Cell Signal.2002;14:717–22. [DOI] [PubMed]
Mattsson JP, Väänänen K, Wallmark B, Lorentzon P.Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. Biochim Biophys Acta.1991;1065:261–8. [DOI] [PubMed]
Der G.An overview of proton pump inhibitors. Gastroenterol Nurs.2003;26:182–90. [DOI] [PubMed]
Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K, et al. Do proton pump inhibitors protect against cancer progression in GERD?Surg Today. 2013;43:831–7. [DOI] [PubMed]
Ohta T, Tajima H, Yachie A, Yokoyama K, Elnemr A, Fushida S, et al. Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components. Int J Oncol.1999;15:33–9. [DOI] [PubMed]
Fais S, De Milito A, You H, Qin W.Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res.2007;67:10627–10630. [DOI] [PubMed]
De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer.2010;127:207–19. [DOI] [PubMed]
Jin UH, Lee SO, Pfent C, Safe S.The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer.2014;14:498. [DOI] [PubMed] [PMC]
Zhang S, Wang Y, Li SJ.Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun.2014;448:424–9. [DOI] [PubMed]
Goh W, Sleptsova-Freidrich I, Petrovic N.Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci.2014;17:439–46. [DOI] [PubMed]
Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res.2014;33:73. [DOI] [PubMed] [PMC]
Morimura T, Fujita K, Akita M, Nagashima M, Satomi A.The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int.2008;24:1087–94. [DOI] [PubMed]
Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol.2013;11:382–8. [DOI] [PubMed]
Ferrari S, Perut F, Fagioli F, Brach Del Prever A, Meazza C, Parafioriti A, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med.2013;11:268. [DOI] [PubMed] [PMC]
Spugnini EP, Baldi A, Buglioni S, Carocci F, de Bazzichini GM, Betti G, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med.2011;9:221. [DOI] [PubMed] [PMC]
Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, et al. Intermittent high dose proton pump inhibitor enhances the antitumour effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res.2015;34:85. [DOI] [PubMed] [PMC]
Svastová E, Hulíková A, Rafajová M, Zat’ovivová M, Gibadulinová A, Casini A, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett.2004;577:439–45. [DOI] [PubMed]
Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem.2008;283:27799–809. [DOI] [PubMed]
Gut MO, Parkkila S, Vernerová Z, Rohde E, Závada J, Höcker M, et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology.2002;123:1889–903. [DOI] [PubMed]
Robertson N, Potter C, Harris AL.Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res.2004;64:6160–5. [DOI] [PubMed]
Dorai T, Swaczuk IS, Pastorek J, Wiernik PH, Dutcher JP.The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer.2005;41:2935–47. [DOI] [PubMed]
Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol.2002;22:7004–14. [DOI] [PubMed] [PMC]
Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res.2011;71:3364–76. [DOI] [PubMed]
McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res.2012;18:3100–11. [DOI] [PubMed] [PMC]
Švastová E, Žilka N, Zat’ovičová M, Gibadulinová A, Čiampor F, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp Cell Res.2003;290:332–45. [DOI] [PubMed]
Ditte P, Dequiedt F, Svastova E, Hulikova A, Ohradanova-Repic A, Zatovicova M, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res.2011;71:7558–67. [DOI] [PubMed]
Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY.Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci.2011;124:1077–87. [DOI] [PubMed]
Worthylake RA, Burridge K.RhoA and ROCK promote migration by limiting membrane protrusions. J Biol Chem.2003;278:13578–84. [DOI] [PubMed]
Swayampakula M, McDonald PC, Vallejo M, Coyaud E, Chafe SC, Westerbeck A, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene.2017;36:6244–61. [DOI] [PubMed] [PMC]
Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A.2000;97:2220–4. [DOI] [PubMed] [PMC]
Meehan J, Ward C, Turnbull A, Bukowski-Wills J, Finch AJ, Jarman EJ, et al. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget.2017;8:42857–75 [DOI] [PubMed] [PMC]
Winum JY, Carta F, Ward C, Mullen P, Harrison D, Langdon SP, et al. Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorg Med Chem Lett.2012;22:4681–5. [DOI] [PubMed]
Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem.2012;55:5591–600. [DOI] [PubMed]
Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget.2015;6:24856–70. [DOI] [PubMed] [PMC]
Battke C, Kremmer E, Mysliwietz J, Gondi G, Dumitru C, Brandau S, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother.2011;60:649–58. [DOI] [PubMed]
Murri-Plesko MT, Hulikova A, Oosterwijk E, Scott AM, Zortea A, Harris AL, et al. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol.2011;657:173–83. [DOI] [PubMed]
Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z, Ditte P, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des.2010;16:3255–63. [DOI] [PubMed]
Supuran CT.Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites.2017;7:E48. [DOI] [PubMed] [PMC]
Supuran CT, Winum JY.Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Med Chem.2015;7:1407–14. [DOI] [PubMed]
Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun.2007;7:13. [PubMed] [PMC]
Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol.1993;11:738–50. [DOI] [PubMed]
Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-α-2a in metastatic renal cell carcinoma patients. World J Urol.2011;29:121–6. [DOI] [PubMed]
Pastorek J, Pastorekova S.Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol.2015;31:52–64. [DOI] [PubMed]
Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, et al. Monoclonal antibody G250 targeting CA IX: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol.2014;45:2455–67. [DOI] [PubMed]
Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med.2004;45:327–37. [PubMed]
Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol.2016;69:767–70. [DOI] [PubMed]
Ozawa Y, Owa T, Yokoi A, Yoshimatsu K, Asada M.The combination of indisulam (E7070) with cisplatin, oxaliplatin and 5-fluorouracil are synergistic in vitro and in vivo. Eur J Cancer Suppl.2004;2:126. [DOI]
Supuran CT.Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov.2008;7:168–81. [DOI] [PubMed]
Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res.2007;13:1816–22. [DOI] [PubMed]
Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol.2011;99:424–31. [DOI] [PubMed]
Doyen J, Parks SK, Marcié S, Pouysségur J, Chiche J.Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front Oncol.2013;2:199. [DOI] [PubMed] [PMC]
Duivenvoorden WC, Hopmans SN, Gallino D, Farrell T, Gerdes C, Glennie D, et al. Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncol Rep.2015;34:1968–76. [DOI] [PubMed]
Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol.2013;108:523–8. [DOI] [PubMed]
Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ.Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites.2018;8:E13. [DOI] [PubMed] [PMC]
Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, et al. Proton-sensing G-protein-coupled receptors. Nature.2003;425:93–8. [DOI] [PubMed]
Yang LV, Radu CG, Roy M, Lee S, McLaughlin J, Teitell MA, et al. Vascular abnormalities in mice deficient for the G protein-coupled receptor GPR4 that functions as a pH sensor. Mol Cell Biol.2007;27:1334–47. [DOI] [PubMed] [PMC]
Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y, et al. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst.2007;99:1313–27. [DOI] [PubMed]
Mogi C, Tobo M, Tomura H, Murata N, He XD, Sato K, et al. Involvement of proton-sensing TDAG8 in extracellular acidification-induced inhibition of proinflammatory cytokine production in peritoneal macrophages. J Immunol.2009;182:3243–51. [DOI] [PubMed]
Castellone RD, Leffler NR, Dong L, Yang LV.Inhibition of tumor cell migration and metastasis by the proton-sensing GPR4 receptor. Cancer Lett.2011;312:197–208. [DOI] [PubMed]
Chen A, Dong L, Leffler NR, Asch AS, Witte ON, Yang LV.Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP/Epac pathway. PLoS ONE.2011;6:e27586. [DOI] [PubMed] [PMC]
Ren J, Zhang L.Effects of ovarian cancer G protein coupled receptor 1 on the proliferation, migration, and adhesion of human ovarian cancer cells. Chin Med J.2011;124:1327–32. [PubMed]
Wyder L, Suply T, Ricoux B, Billy E, Schnell C, Baumgarten BU, et al. Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor. Angiogenesis.2011;14:533–44. [DOI] [PubMed]
Dong L, Li Z, Leffler NR, Asch AS, Chi JT, Yang LV.Acidosis activation of the proton-sensing GPR4 receptor stimulates vascular endothelial cell inflammatory responses revealed by transcriptome analysis. PLoS ONE.2013;8:e61991. [DOI] [PubMed] [PMC]
Murakami N, Yokomizo T, Okuno T, Shimizu T.G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem.2004;279:42484–91. [DOI] [PubMed]
Wang JQ, Kon J, Mogi C, Tobo M, Damirin A, Sato K, et al. TDAG8 is a proton-sensing and psychosine-sensitive G-protein-coupled receptor. J Biol Chem.2004;279:45626–33. [DOI] [PubMed]
Roland CL, Arumugam T, Deng D, Liu SH, Philip B, Gomez S, et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res.2014;74:5301–10. [DOI] [PubMed] [PMC]
Ishii S, Kihara Y, Shimizu T.Identification of T cell death-associated gene 8 (TDAG8) as a novel acid sensing G-protein-coupled receptor. J Biol Chem.2005;280:9083–7. [DOI] [PubMed]
Radu CG, Nijagal A, McLaughlin J, Wang L, Witte ON.Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. Proc Natl Acad Sci U S A.2005;102:1632–7. [DOI] [PubMed] [PMC]
Liu JP, Nakakura T, Tomura H, Tobo M, Mogi C, Wang JQ, et al. Each one of certain histidine residues in G-protein-coupled receptor GPR4 is critical for extracellular proton-induced stimulation of multiple G-protein-signaling pathways. Pharmacol Res.2010;61:499–505. [DOI] [PubMed]
Tobo M, Tomura H, Mogi C, Wang JQ, Liu JP, Komachi M, et al. Previously postulated “ligand-independent” signaling of GPR4 is mediated through proton-sensing mechanisms. Cell Signal.2007;19:1745–53. [DOI] [PubMed]
Zhang Y, Feng Y, Justus CR, Jiang W, Li Z, Lu JQ, et al. Comparative study of 3D morphology and functions on genetically engineered mouse melanoma cells. Integr Biol (Camb).2012;4:1428–36. [DOI] [PubMed]
Sin WC, Zhang Y, Zhong W, Adhikarakunnathu S, Powers S, Hoey T, et al. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene.2004;23:6299–303. [DOI] [PubMed]
Li J, Guo B, Wang J, Cheng X, Xu Y, Sang J.Ovarian cancer G protein coupled receptor 1 suppresses cell migration of MCF7 breast cancer cells via a Gα12/13-Rho-Rac1 pathway. J Mol Signal.2013;8:6. [DOI] [PubMed] [PMC]
Li H, Wang D, Singh LS, Berk M, Tan H, Zhao Z, et al. Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. PloS One.2009:4:e5705. [DOI] [PubMed] [PMC]
Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J.2018;32:1170–83. [DOI] [PubMed] [PMC]
Zhu H, Guo S, Zhang Y, Yin J, Yin W, Tao S, et al. Proton-sensing GPCR-YAP signalling promotes cancer-associated fibroblast activation of mesenchymal stem cells. Int J Biol Sci.2016;12:389–96. [DOI] [PubMed] [PMC]
de Vallière C, Cosin-Roger J, Simmen S, Atrott K, Melhem H, Zeitz J, et al. Hypoxia positively regulates the expression of pH-sensing G-protein-coupled receptor OGR1 (GPR68). Cell Mol Gastroenterol Hepatol.2016;2:796–810. [DOI] [PubMed] [PMC]
Li S, Huang S, Peng SB.Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol.2005;27;1329–39. [PubMed]
Ihara Y, Kihara Y, Hamano F, Yanagida K, Morishita Y, Kunita A, et al. The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. Proc Natl Acad Sci U S A.2010;107:17309–14. [DOI] [PubMed] [PMC]
Ryder C, McColl K, Zhong F, Distelhorst CW.Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk. J Biol Chem.2012;287:27863–75. [DOI] [PubMed] [PMC]
Kyaw H, Zeng Z, Su K, Fan P, Shell BK, Carter KC, et al. Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene. DNA Cell Biol.1998;17:493–500. [DOI] [PubMed]
Radu CG, Cheng D, Nijagal A, Riedinger M, McLaughlin J, Yang LV, et al. Normal immune development and glucocorticoid-induced thymocyte apoptosis in mice deficient for the T-cell death-associated gene 8 receptor. Mol Cell Biol.2006;26:668–77. [DOI] [PubMed] [PMC]
Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene.2017;36:5829–39. [DOI] [PubMed]
Weng Z, Fluckiger AC, Nisitani S, Wahl MI, Le LQ, Hunter CA, et al. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci U S A.1998;95:12334–9. [DOI] [PubMed] [PMC]
Zohn IE, Klinger M, Karp X, Kirk H, Symons M, Chrzanowska-Wodnicka M, et al. G2A is an oncogenic G protein-coupled receptor. Oncogene.2000;19:3866–77. [DOI] [PubMed]
Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A.2017;114:580–5. [DOI] [PubMed] [PMC]
Cheng WY, Huynh H, Chen P, Peña-Llopis S, Wan Y.Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife.2016;5:e18501. [DOI] [PubMed] [PMC]
Taracido IC, Harrington EM, Hersperger R, Lattmann R, Miltz W, Weigand K, inventors. Imidazo pyridine derivatives. United States patent US20090291942A1.2009May5.
Zhang L, Li P, Hsu T, Aguilar HR, Frantz DE, Schneider JW, et al. Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression. Differentiation.2011;81:233–42. [DOI] [PubMed] [PMC]
McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K, et al. Histone acetylation regulates intracellular pH. Mol Cell.2013;49:310–21. [DOI] [PubMed] [PMC]
Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res.2009;69:3802–9. [DOI] [PubMed]
Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol.2010;28:1358–65. [DOI] [PubMed] [PMC]
Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol.2009;174:1619–28. [DOI] [PubMed] [PMC]
Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamics markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia.2008;10:303–13. [DOI] [PubMed] [PMC]
West AC, Johnstone RW.New and emerging HDAC inhibitors for cancer treatment. J Clin Invest.2014;124:30–9. [DOI] [PubMed] [PMC]
Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, et al. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer.2016;115:929–39. [DOI] [PubMed] [PMC]
Rivera S, Leteur C, Mégnin F, Law F, Martins I, Kloos I, et al. Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. Oncotarget.2017;8:56210–27. [DOI] [PubMed] [PMC]
Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE.Histone deactylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer.2013;108:748–54. [DOI] [PubMed] [PMC]
Pfister SX, Ashworth A.Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov.2017;16:241–63. [DOI] [PubMed]
Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget.2017;8:38022–43. [DOI] [PubMed] [PMC]
Faleiro I, Leão R, Binnie A, de Mello RA, Maia AT, Castelo-Branco P.Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget.2017;8:12484–500. [DOI] [PubMed] [PMC]
Ronnekliev-Kelly SM, Sharma A, Ahuja N.Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treat Rev.2017;55:200–8. [DOI] [PubMed]
Shi W, Lawrence YR, Choy H, Werner-Wasik M, Andrews DW, Evans JJ, et al. Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neurooncol.2014;118:313–19. [DOI] [PubMed]
Fushida S, Kaji M, Oyama K, Hirono Y, Nezuka H, Takeda T, et al. Randomized phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as a second-line therapy for patients with advanced gastric cancer. Onco Targets Ther.2015;8:939–41. [DOI] [PubMed] [PMC]
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer.2011;104:1828–35. [DOI] [PubMed] [PMC]
Makovitzki A, Fink A, Shai Y.Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defence-like lytic peptides. Cancer Res.2009;69:3458–63. [DOI] [PubMed]
Vāvere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, et al. A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Cancer Res.2009;69:4510–6. [DOI] [PubMed] [PMC]
Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A.2007;104:7893–8. [DOI] [PubMed] [PMC]
Adochite R, Moshnikova A, Carlin SD, Guerrieri RA, Andreev OA, Lewis JS, et al. Targeting breast tumors with pH (low) insertion peptides. Mol Pharm.2014;11:2896–905. [DOI] [PubMed] [PMC]
Tapmeier TT, Moshnikova A, Beech J, Allen D, Kinchesh P, Smart S, et al. The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions. Proc Natl Acad Sci U S A.2015;112:9710–5. [DOI] [PubMed] [PMC]
Wijesinghe D, Arachchige MC, Lu A, Reshetnyak YK, Andreev OA.pH dependent transfer of nano-pores into membrane of cancer cells to induce apoptosis. Sci Rep.2013;3:3560. [DOI] [PubMed] [PMC]
Li SY, Liu LH, Jia HZ, Qiu WX, Rong L, Cheng H, et al. A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy. Chem Commun.2014;50:11852–5. [DOI] [PubMed]
Xu Z, Liu S, Kang Y, Wang M.Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale.2015;7:5859–68. [DOI] [PubMed]
Sethuraman VA, Na K, Bae YH.pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules.2006;7:64–70. [DOI] [PubMed]
Sethuraman VA, Lee MC, Bae YH.A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res.2008;25:657–66. [DOI] [PubMed]
Savariar EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res.2013;73:855–64. [DOI] [PubMed] [PMC]
Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv.2014;32:693–710. [DOI] [PubMed]
Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, et al. A first-in-class, first-inhuman, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer.2013;108:1061–70. [DOI] [PubMed] [PMC]
Coriat R, Faivre SJ, Dreyer C, Mir O, Bouattour M, Goldwasser F, et al. First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas. J Clin Oncol.2012;30 suppl15:2557.
Tang TB, Smith S, Flynn BW, Stevenson JT, Gundlach AM, Reekie HM, et al. Implementation of wireless power transfer and communications for an implantable ocular drug delivery system. IET Nanobiotechnol.2008;2:72–9. [DOI] [PubMed]
Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI, et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med.2015;7:284ra57. [DOI]
